Login to Your Account

Ablynx is Back in the Game with Ozoralizumab

By Cormac Sheridan
Staff Writer

Tuesday, June 26, 2012

New data from an open-label Phase II extension study prompted Ablynx NV to claim Monday that its tumor necrosis factor alpha (TNF-alpha) inhibitor ozoralizumab (ATN-103) was back in the game.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription